Hjem › Eggstokkreft › Michigan › Detroit
Kliniske studier for Eggstokkreft i Detroit, MI
26 studier for Eggstokkreft søker deltakere på steder i og rundt Detroit (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
The Vanguard Study: Testing a New Way to Screen for Cancer
RekruttererFrivillige helsepersonell ønskes velkommen
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RekruttererFase 2/3
- Henry Ford Hospital, Detroit
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RekruttererFase 1/2
- Research Site, Detroit
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
RekruttererObservasjonsstudie
- Henry Ford Health, Detroit
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RekruttererFase 2
- Site 0101 - Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RekruttererFase 3
- Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RekruttererFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
RekruttererFase 2
- Karmanos Cancer Institute - Detroit /ID# 277085, Detroit
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RekruttererFase 3
- Henry Ford Cancer - Detroit, Detroit
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
RekruttererFase 2
- Karmanos Cancer Institute, Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruttererFase 1
- Karmanos Cancer Institiute, Detroit
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
RekruttererFase 3
- Karmanos Cancer Institute, Detroit
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RekruttererFase 1
- Karmanos Cancer Institute, Detroit
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
RekruttererFase 1
- Karmanos Cancer Center, Detroit
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RekruttererFase 3
- Henry Ford Health Saint John Hospital, Detroit
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
RekruttererFase 1
- Karmanos Cancer Institute, Detroit
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekruttererFase 1/2
- Henry Ford Health Hospital, Detroit
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
RekruttererFase 2
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
RekruttererFase 2
- Karmanos Cancer Institute - Detroit /ID# 272112, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
RekruttererFase 1
- Karmanos Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
RekruttererFase 1
- Karmanos Cancer Institute, Detroit
Eggstokkreft-studier i andre byer
- Houston, TX89 studier
- New York City, NY69 studier
- Boston, MA61 studier
- Los Angeles, CA50 studier
- Nashville, TN49 studier
- Arlington, VA46 studier
- Philadelphia, PA44 studier
- Columbus, OH39 studier
- St. Louis, MO38 studier
- Chicago, IL36 studier
- San Antonio, TX31 studier
- Cleveland, OH30 studier
Andre studier i Detroit
- Ikke-småcellet lungekreft44 studier
- Brystkreft33 studier
- Kreft (alle typer)29 studier
- Kolorektal kreft26 studier
- Metastatisk kreft24 studier
- Prostatakreft22 studier
- Endometriekreft21 studier
- Lungekreft20 studier
- Multipelt myelom19 studier
- Mavekreft16 studier
- Plateepitelcancer i hode og hals15 studier
- Akut myelogen leukemi14 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.